On January 28, 2026, Morgan Stanley analyst Terence Flynn upgraded Johnson & Johnson (JNJ) to an “Overweight” rating, suggesting potential for the stock to appreciate significantly from its current trading level. Flynn’s price target of $262 represents a notable upside from JNJ’s recent trading price of $227.72. This rating shift could signal confidence among institutional investors regarding JNJ’s growth prospects, thereby influencing purchasing decisions ahead.
Recent Price Action
In the latest trading session, Johnson & Johnson’s stock experienced a gain of 1.46%, increasing by $3.28 to close at $227.72. With a market capitalization of approximately $548.64 billion, JNJ remains a significant player in the healthcare sector. Recent trading volumes have shown notable activity with 8,961,359 shares exchanged, slightly exceeding the average volume of 8,830,849 shares. The stock has shown enhancements in price stability, highlighted by a low beta of 0.333 which indicates reduced volatility compared to broader market movements. Over the past year, JNJ has ranged dramatically, experiencing a 52-week high of $0.98 and a low of $60.93. This stability might appeal to investors seeking less volatile assets in their portfolios.
[chart type=’price’ value=’JNJ’]
Historical Performance
An evaluation of JNJ’s performance reflects a positive trajectory in the medium to long term, driven by various market conditions. Over the past 30 days, the stock has gained 3.75%, building on a quarterly increase of 12.93%. Perhaps most impressively, JNJ has delivered a remarkable annual return of 47.67%. This performance underscores the stock’s resilience amid broader market fluctuations, supported by a 1.9% weekly volatility, which speaks to steady investor confidence. The average trading volume over the last ten days stands at approximately 10,149,847, which signifies consistent interest from traders, while the broader 3-month average slightly trails at 8,306,705 shares per day.
[chart type=’performance’ value=’JNJ’]
Earnings Analysis
In the most recent earnings report dated October 14, 2025, Johnson & Johnson surpassed expectations with an earnings per share (EPS) of $2.80, comfortably exceeding the estimated $2.76. This 1.45% earnings surprise reflects the company’s effective cost management and strong product demand. Notably, the previous quarter also saw JNJ exceed EPS estimates, recording $2.77 against an estimate of $2.68, yielding a surprise of 3.36%. Such consistent outperformance in earnings could signal a reliable revenue model and sound operational fundamentals, likely contributing to the upgraded rating from Morgan Stanley.
[chart type=’income-bar-chart’ value=’JNJ’]
Analyst Consensus View
The consensus sentiment surrounding JNJ is predominantly positive, with 19 analysts weighing in collectively; 10 have issued a “Buy” rating, while 9 have opted for “Hold.” Notably, no analysts recommend a sell, indicating a solid foundation for JNJ in today’s market. The average price target sits at approximately $228.21, with the highest estimate reaching $265, while the lowest suggests a price of $197. The collective outlook reflects optimism about JNJ’s future performance and growth prospects, particularly following the recent rating upgrade.
[chart type=’analyst-ratings’ value=’JNJ’]
Stock Grading or Fundamental View
Johnson & Johnson’s Stocks Telegraph Grade stands at a level of 50, suggesting a fair assessment of the company’s overall health and investment profile relative to its peers. This moderate score indicates that while JNJ possesses solid fundamentals—evident in its earnings beat and consistent historical performance—the market is not currently reflecting the full potential of its innovative pipeline and market leadership.
[chart type=’st-cards’ value=’JNJ’]
Conclusion
Johnson & Johnson represents a compelling investment opportunity primarily for long-term growth-oriented investors. With its recent upgrade to an “Overweight” rating, solid earnings surprises, and favorable historical performance, the stock appears poised for upward movement. Nevertheless, investors should remain aware of inherent risks associated with market volatility, as health sector dynamics can sometimes be unpredictable. Overall, JNJ is worth considering for those looking to balance their portfolios with a stable and fundamentally sound leader in the healthcare space.